-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $20

Benzinga·07/27/2026 13:03:19
Listen to the news
Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $17 to $20.